問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

National Taiwan University Hospital

更新時間：2023-09-19

黃詩喻
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

96Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃詩喻

List

133Cases

2025-06-30 - 2032-05-01

Phase II

Active
A phase 2, open-label, multi-population trial evaluating the efficacy and safety of ASP5541 in participants with advanced prostate cancer.

  • Condition/Disease

    * Percentage of mCRPC participants who have not used ARPI and whose PSA has decreased by ≥90% from baseline.* Incidence of no mineral corticosteroid toxicity (defined as no ≥ Grade 1 hypokalemia and no ≥ Grade 2 hypertension).* Percentage of mHSPC participants with PSA ≤ 0.2 ng/mL at 8 months.* DLT, AE, SAE, laboratory test results (including chemistry, hematology, and urinalysis), ECG, vital signs, physical examination, and ECOG performance status score.

  • Test Drug

    "Chengda" Prednisone Tablets 5 mg (Penisol) "Boli" Concentrate Tablets 5 mg (Penisol) Abiraterone acetate ASP5541 (Abiraterone decanoate) Cosyntropin Prednisone Abiraterone Tablets 250 mg Prednisone Tablets Erezhi Film-Coated Tablets 250 mg Lerdan Tablets

Participate Sites
6Sites

Recruiting6Sites

2025-08-01 - 2032-12-31

Phase III

Active
AcTFirst: A phase III, open-label, multicenter, randomized trial comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration-resistant prostate cancer

  • Condition/Disease

    rPFS was defined as the time elapsed from the date of randomization to the date of the first documented radiographic disease progression or death from any cause as assessed by the Blinded Independent Central Review Committee (BICR) using conventional imaging and Prostate Cancer Working Group 3 (PCWG3) revised RECIST version 1.1 criteria, whichever occurred first.

  • Test Drug

    AAA617 AAA817 Abiraterone Cabazitaxel

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2031-06-30

Not yet recruiting
A phase 3, open-label, randomized trial was conducted to evaluate the efficacy and safety of RLY-2608 + Fulvestrant compared to Capivasertib + Fulvestrant in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer that relapsed or progressed during or after CDK4/6 inhibitor therapy.

  • Condition/Disease

    Locally advanced or metastatic breast cancer

  • Test Drug

    Capivasertib Capivasertib Fulvestrant RLY-2608

Participate Sites
6Sites

Recruiting6Sites

2025-09-01 - 2027-05-31

Phase I/II

Active
A first-in-human dose escalation and expansion trial of BDC-4182 as a single agent in patients with advanced gastric and gastroesophageal cancer in stage 1/2.

  • Condition/Disease

    Advanced gastric cancer, advanced gastroesophageal cancer

  • Test Drug

    BDC-4182

Participate Sites
6Sites

Recruiting6Sites

2025-02-07 - 2032-12-31

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2024-11-01 - 2029-12-31

Phase III

Active
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

  • Condition/Disease

    Colorectal Neoplasms

  • Test Drug

    Injectable solution Injectable preparation Injectable preparation

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2025-02-03 - 2029-12-23

Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2029-06-30

Phase III

Active
A phase 3, randomized, multicenter, open-label study was conducted to investigate the use of IDRX-42 (GSK6042981) versus Sunitinib in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who had received imatinib treatment (StrateGIST 3).

  • Condition/Disease

    Metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) following treatment with imatinib.

  • Test Drug

    IDRX-42 (GSK6042981) Sunitinib

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2032-01-31

Phase II/III

Active
A phase 2/3, open-label, randomized trial evaluating the efficacy of telisotuzumab adizutecan monotherapy versus osimertinib in patients with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer who have progressed after third-generation EGFR TKI therapy, compared with standard of care. - AndroMETa-Lung-713

  • Condition/Disease

    Subjects with locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after third-generation EGFR TKI treatment

  • Test Drug

    Telisotuzumab Adizutecan (ABBV-400)

Participate Sites
8Sites

Recruiting8Sites

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    Injectable drugs Subcutaneous injections Injectable drugs Injectable drugs Injectable drugs

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB